Standard BioTools

Standard BioTools Goodwill

The Goodwill of Standard BioTools (LAB) as of Sep 20, 2026 is 111.30 M USD. In the previous year, Goodwill was 106.32 M USD — a change of 4.68% (higher).

Goodwill

111.30 MUSD

YoY

4.68%

Last updated:

Goodwill of Standard BioTools is 2026 111.30 M USD. Goodwill of Standard BioTools was 2025 106.32 M USD. It decreases by 4.68% higher compared to the previous year.

The Standard BioTools Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2017
104.11 M USD
Jan 1, 2018
104.11 M USD
Jan 1, 2019
104.11 M USD
Jan 1, 2020
106.56 M USD
Jan 1, 2021
106.38 M USD
Jan 1, 2022
106.25 M USD
Jan 1, 2023
106.32 M USD
Jan 1, 2024
111.30 M USD
The Standard BioTools Goodwill history
YEARGoodwillYoY
111.30 MUSD+4.68%
106.32 MUSD+0.06%
106.25 MUSD-0.12%
106.38 MUSD-0.17%
106.56 MUSD+2.36%
104.11 MUSD0.00%
104.11 MUSD0.00%
104.11 MUSD0.00%
104.11 MUSD0.00%
104.11 MUSD0.00%
104.11 MUSD
Access this data via the Eulerpool API

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Goodwill of Standard BioTools is 111.30 M USD in 2026.

Goodwill of Standard BioTools changed from 106.32 M USD to 111.30 M USD, representing a 4.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Standard BioTools historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Standard BioTools

All Key Metrics — Standard BioTools